Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Ex-ArthroCare CEO heads lung disorder firm

This article was originally published in Clinica

  • News

Executive Summary

Michael Baker, the former president and CEO of tissue ablation technology specialist ArthroCare, has been appointed to lead Pulmonx , a Redwood City, California firm specialising in minimally-invasive treatments for pulmonary disorders. Mr. Baker was at ArthroCare for 11 years, but left in February under controversial circumstances, when an internal audit found evidence of improper business conduct by the company (see Improper practices prompt CEO to depart ArthroCare, 19/2/09). The appointment comes at a time when Pulmonx is poised for global commercialisation of its new Chartis System, a tool for assessing lung function. The product was FDA-cleared in July, and the firm is awaiting approval for CE marking.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

News We're Watching: LDT Final Rule Near Publication, Zimmer ROSA Used In Shoulder Surgery, $60M For Menopause Clinic

Epitel Gets 510(k) Clearance On Remote EEG Technology

Valuable Health Data Sources For Medtech Industry Come A Step Closer In The EU

Rise In Class I Device Recalls A ‘Grave Concern,’ Says FDA’s Anne Reid

See All
UsernamePublicRestriction

Register

MT043948

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By